2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, neoplasm, stomach disorderActive, not recruitingPhase 32026-09-28NCT03653507
IMPACT: Improving Maternal Postpartum Access to Care Through TelemedicineDeath, Female Urogenital Diseases and Pregnancy Complications, Infections, Maternal Death, Parental Death, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, Wound Infection, breast disorder, cardiovascular disorder, hypertensive disorder, mastitis, pregnancy disorder, puerperal disorder, skin disorder, vascular disorderRecruitingNot applicable2026-09-02NCT06218355